Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.68 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.60 |
| ▸ | PIM1 | P11309 | 3/20 | 0.60 |
| ▸ | STK3 | Q13188 | 3/20 | 0.60 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.60 |
| ▸ | NTRK3 | Q16288 | 3/20 | 0.60 |
| ▸ | TAOK1 | Q7L7X3 | 3/20 | 0.60 |
| ▸ | HIPK4 | Q8NE63 | 3/20 | 0.60 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.60 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.60 |
| ▸ | MAP4K5 | Q9Y4K4 | 3/20 | 0.60 |
| ▸ | LCK | P06239 | 2/20 | 0.60 |
| ▸ | RET | P07949 | 2/20 | 0.60 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.60 |
| ▸ | BLK | P51451 | 2/20 | 0.60 |
| ▸ | GSK3B | P49841 | 2/20 | 0.60 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.60 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.60 |
| ▸ | PLK4 | O00444 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1333801 | 0.81 | KDR (1.00) | KDRROCK2MAP4K4PIM1STK3 | |
| SCHEMBL1335342 | 0.79 | KDR (1.00) | KDRROCK2MAP4K4PIM1STK3 | |
| SCHEMBL1335271 | 0.79 | KDR (0.82) | KDRROCK2MAP4K4PIM1STK3 | |
| SCHEMBL1335607 | 0.79 | KDR (0.82) | KDRROCK2MAP4K4PIM1STK3 | |
| SCHEMBL1334194 | 0.79 | KDR (0.81) | KDRROCK2MAP4K4PIM1STK3 | |
| SCHEMBL1335474 | 0.79 | KDR (1.00) | KDRROCK2MAP4K4PIM1STK3 | |
| SCHEMBL1333899 | 0.79 | KDR (0.65) | KDRROCK2MAP4K4PIM1STK3 | |
| SCHEMBL19608227 | 0.76 | PIK3CD (0.64) | KDRROCK2MAP4K4PIM1STK3 | |
| SCHEMBL1333209 | 0.76 | KDR (0.57) | KDRROCK2MAP4K4PIM1STK3 | |
| SCHEMBL1335304 | 0.76 | KDR (0.85) | KDRROCK2MAP4K4PIM1STK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275630-A1 | ISOINDOLINONE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2011-11-10 | — | — | US | disclosed |
| US-20100076051-A1 | ISOINDOLINONE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-03-25 | — | — | US | disclosed |
| US-20060287370-A1 | Isoindolinone kinase inhibitors | CURTIN MICHAEL L | 2006-12-21 | — | — | US | disclosed |
| US-7129260-B2 | Isoindolinone kinase inhibitors | ABBOTT LABORATORIES (US) | 2006-10-31 | — | — | US | disclosed |
| US-20050026976-A1 | Isoindolinone kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287370-A1 | Isoindolinone kinase inhibitors | ABL1, LCK, MAP3K7 | KDR 527/4885ROCK2 264/4885MAP4K4 73/4885 |
| US-20050026976-A1 | Isoindolinone kinase inhibitors | ABL1, LCK, MAP3K7 | KDR 527/4885ROCK2 264/4885MAP4K4 73/4885 |
| US-20100076051-A1 | ISOINDOLINONE KINASE INHIBITORS | ABL1, LCK, MAP3K7 | KDR 527/4885ROCK2 264/4885MAP4K4 73/4885 |
| US-20110275630-A1 | ISOINDOLINONE KINASE INHIBITORS | MAP3K7, MAP3K5, MAP3K20 | KDR 909/4885ROCK2 316/4885MAP4K4 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.